Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide.
No risks detected for 540701 from our risk checks.
Dishman Carbogen Amcis Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹216.65|
|52 Week High||₹102.55|
|52 Week Low||₹259.50|
|1 Month Change||9.72%|
|3 Month Change||3.61%|
|1 Year Change||39.59%|
|3 Year Change||-7.18%|
|5 Year Change||n/a|
|Change since IPO||-38.32%|
Recent News & Updates
|540701||IN Life Sciences||IN Market|
Return vs Industry: 540701 underperformed the Indian Life Sciences industry which returned 46.8% over the past year.
Return vs Market: 540701 underperformed the Indian Market which returned 62.5% over the past year.
Stable Share Price: 540701 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 540701's weekly volatility (8%) has been stable over the past year.
About the Company
Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, intermediates, phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D products, fine chemicals, hand and body wash, sanitisers, antiseptics, and various pharmaceutical and cosmetic-related products, as well as generic and highly potent active pharmaceutical ingredients.
Dishman Carbogen Amcis Fundamentals Summary
|540701 fundamental statistics|
Is 540701 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|540701 income statement (TTM)|
|Cost of Revenue||₹5.41b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 28, 2021
|Earnings per share (EPS)||-8.14|
|Net Profit Margin||-6.42%|
How did 540701 perform over the long term?See historical performance and comparison
Is Dishman Carbogen Amcis undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 540701 (₹216.65) is trading above our estimate of fair value (₹9.81)
Significantly Below Fair Value: 540701 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 540701 is unprofitable, so we can't compare its PE Ratio to the Indian Life Sciences industry average.
PE vs Market: 540701 is unprofitable, so we can't compare its PE Ratio to the Indian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 540701's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 540701 is good value based on its PB Ratio (0.6x) compared to the IN Life Sciences industry average (3.6x).
How is Dishman Carbogen Amcis forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 540701 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (6.7%).
Earnings vs Market: 540701 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 540701's is expected to become profitable in the next 3 years.
Revenue vs Market: 540701's revenue (13% per year) is forecast to grow faster than the Indian market (12.6% per year).
High Growth Revenue: 540701's revenue (13% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 540701's Return on Equity is forecast to be high in 3 years time
How has Dishman Carbogen Amcis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 540701 is currently unprofitable.
Growing Profit Margin: 540701 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 540701 is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare 540701's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 540701 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.7%).
Return on Equity
High ROE: 540701 has a negative Return on Equity (-2.24%), as it is currently unprofitable.
How is Dishman Carbogen Amcis's financial position?
Financial Position Analysis
Short Term Liabilities: 540701's short term assets (₹16.6B) exceed its short term liabilities (₹12.5B).
Long Term Liabilities: 540701's short term assets (₹16.6B) exceed its long term liabilities (₹13.8B).
Debt to Equity History and Analysis
Debt Level: 540701's debt to equity ratio (27.9%) is considered satisfactory.
Reducing Debt: 540701's debt to equity ratio has increased from 20.3% to 27.9% over the past 5 years.
Debt Coverage: 540701's debt is well covered by operating cash flow (32.3%).
Interest Coverage: 540701's interest payments on its debt are well covered by EBIT (7.1x coverage).
What is Dishman Carbogen Amcis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 540701's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 540701's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 540701's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 540701's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 540701 is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 540701's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mark Griffiths (57 yo)
Mr. Mark Christopher Griffiths serves as Global Chief Executive Officer at Dishman Pharmaceuticals and Chemicals Limited. Mr. Griffiths serves as Global Chief Executive Officer at Dishman Carbogen Amcis Li...
Experienced Board: 540701's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Dishman Carbogen Amcis Limited's employee growth, exchange listings and data sources
- Name: Dishman Carbogen Amcis Limited
- Ticker: 540701
- Exchange: BSE
- Founded: 1983
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹33.975b
- Shares outstanding: 156.78m
- Website: https://imdcal.com
Number of Employees
- Dishman Carbogen Amcis Limited
- Dishman Corporate House
- Iscon–Bopal Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/27 12:04|
|End of Day Share Price||2021/10/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.